Tags

Type your tag names separated by a space and hit enter

Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Gut. 2006 Nov; 55(11):1631-8.Gut

Abstract

BACKGROUND

The management of patients with chronic hepatitis C who have relapsed or failed to respond to interferon based therapies is an important issue facing hepatologists.

AIMS

We evaluated the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in this population by conducting a multicentre open label study.

PATIENTS

Data from adults with detectable serum hepatitis C virus (HCV) RNA who had not responded or had relapsed after previous conventional interferon or conventional interferon/ribavirin combination therapy were analysed.

METHODS

Patients were retreated with peginterferon alfa-2a (40KD) 180 microg/week plus ribavirin 800 mg/day for 24 or 48 weeks at the investigators' discretion. The study was conceived before the optimal dose of ribavirin (1000/1200 mg/day) for patients with genotype 1 was known. The primary endpoint was sustained virological response (SVR), defined as undetectable HCV RNA (<50 IU/ml) after 24 weeks of follow up. The analysis was conducted by intention to treat.

RESULTS

A total of 312 patients (212 non-responders, 100 relapsers) were included. Of these, 28 patients were treated for 24 weeks and 284 for 48 weeks. Baseline characteristics between non-responders and relapsers were similar although more non-responders had genotype 1 infection (87% v 69%). Overall SVR rates were 23% (48/212) for non-responders and 41% (41/100) for relapsers. When data were analysed by genotype, SVR rates were 24% (61/253) in genotype 1 and 47% (28/59) in genotype 2/3.

CONCLUSIONS

These results in a large patient cohort demonstrate that it is possible to cure a proportion of previous non-responders and relapsers by retreating with peginterferon alfa-2a (40KD) plus ribavirin.

Authors+Show Affiliations

Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, M5G 2C4 Canada. morris.sherman@uhn.on.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16709661

Citation

Sherman, M, et al. "Peginterferon Alfa-2a (40KD) Plus Ribavirin in Chronic Hepatitis C Patients Who Failed Previous Interferon Therapy." Gut, vol. 55, no. 11, 2006, pp. 1631-8.
Sherman M, Yoshida EM, Deschenes M, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut. 2006;55(11):1631-8.
Sherman, M., Yoshida, E. M., Deschenes, M., Krajden, M., Bain, V. G., Peltekian, K., Anderson, F., Kaita, K., Simonyi, S., Balshaw, R., & Lee, S. S. (2006). Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut, 55(11), 1631-8.
Sherman M, et al. Peginterferon Alfa-2a (40KD) Plus Ribavirin in Chronic Hepatitis C Patients Who Failed Previous Interferon Therapy. Gut. 2006;55(11):1631-8. PubMed PMID: 16709661.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. AU - Sherman,M, AU - Yoshida,E M, AU - Deschenes,M, AU - Krajden,M, AU - Bain,V G, AU - Peltekian,K, AU - Anderson,F, AU - Kaita,K, AU - Simonyi,S, AU - Balshaw,R, AU - Lee,S S, AU - ,, Y1 - 2006/05/18/ PY - 2006/5/20/pubmed PY - 2006/11/15/medline PY - 2006/5/20/entrez SP - 1631 EP - 8 JF - Gut JO - Gut VL - 55 IS - 11 N2 - BACKGROUND: The management of patients with chronic hepatitis C who have relapsed or failed to respond to interferon based therapies is an important issue facing hepatologists. AIMS: We evaluated the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in this population by conducting a multicentre open label study. PATIENTS: Data from adults with detectable serum hepatitis C virus (HCV) RNA who had not responded or had relapsed after previous conventional interferon or conventional interferon/ribavirin combination therapy were analysed. METHODS: Patients were retreated with peginterferon alfa-2a (40KD) 180 microg/week plus ribavirin 800 mg/day for 24 or 48 weeks at the investigators' discretion. The study was conceived before the optimal dose of ribavirin (1000/1200 mg/day) for patients with genotype 1 was known. The primary endpoint was sustained virological response (SVR), defined as undetectable HCV RNA (<50 IU/ml) after 24 weeks of follow up. The analysis was conducted by intention to treat. RESULTS: A total of 312 patients (212 non-responders, 100 relapsers) were included. Of these, 28 patients were treated for 24 weeks and 284 for 48 weeks. Baseline characteristics between non-responders and relapsers were similar although more non-responders had genotype 1 infection (87% v 69%). Overall SVR rates were 23% (48/212) for non-responders and 41% (41/100) for relapsers. When data were analysed by genotype, SVR rates were 24% (61/253) in genotype 1 and 47% (28/59) in genotype 2/3. CONCLUSIONS: These results in a large patient cohort demonstrate that it is possible to cure a proportion of previous non-responders and relapsers by retreating with peginterferon alfa-2a (40KD) plus ribavirin. SN - 0017-5749 UR - https://www.unboundmedicine.com/medline/citation/16709661/Peginterferon_alfa_2a__40KD__plus_ribavirin_in_chronic_hepatitis_C_patients_who_failed_previous_interferon_therapy_ L2 - http://gut.bmj.com/cgi/pmidlookup?view=long&amp;pmid=16709661 DB - PRIME DP - Unbound Medicine ER -